NMC
NBIX icon

Nine Masts Capital’s Neurocrine Biosciences NBIX Stock Holding History

Nine Masts Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-9,669
Closed -$852K – 207
2019
Q1 		$852K Buy
+9,669
New +$808K 0.27% 39

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nine Masts Capital's NBIX Position: Q2 2019 in Review

Nine Masts Capital sold out of Neurocrine Biosciences (NBIX) in Q2 2019, closing a stake of 9,669 shares — an estimated $852K sold.

Nine Masts Capital first reported a position in NBIX in Q1 2019 and held it in 1 quarter. The position peaked at $852K in Q1 2019. 302 funds tracked by Wall St. Rank hold NBIX as of Q2 2019.

  • Nine Masts Capital reported no remaining Neurocrine Biosciences position as of Q2 2019 after selling out during the quarter.
  • Nine Masts Capital sold 9,669 Neurocrine Biosciences shares in Q2 2019, an estimated $852K.
  • Nine Masts Capital first reported a position in Neurocrine Biosciences in Q1 2019 and held it in 1 quarter.
  • Nine Masts Capital's Neurocrine Biosciences position peaked at $852K in Q1 2019.
  • 302 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2019.

Based on Nine Masts Capital's 13F filing for Q2 2019, filed 8 Aug 2019.